Decompensated heart failure after one year of successful therapy with mavacamten: a case report.
- 1Department of Medical and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, Rome 00161, Italy.
Abstract
Cardiac myosin inhibition is the first disease-specific therapeutic strategy for obstructive hypertrophic cardiomyopathy. Mavacamten, the first-in-class agent, has demonstrated an excellent safety profile and sustained efficacy in both clinical trials and real-world practice. However, its safe use requires careful monitoring and thorough patient education regarding potential drug-drug interactions. We report a case of acute heart failure occurring after long-term clinical stability on mavacamten following concomitant fluconazole administration. It is reasonable to assume that the pharmacokinetic interaction resulted in excessive mavacamten exposure, leading to transient systolic dysfunction, severe functional mitral regurgitation, and adverse left ventricular remodelling. This case report highlights the consequences of pharmacological interactions between mavacamten and a strong CYP2C19 inhibitor. Drug-drug interaction should always be considered and systematically excluded in a patient presenting with unexplained heart failure and left ventricular remodelling during mavacamten therapy.
Related
- Case Report: Successful treatment of verruciform acanthotic vulvar intraepithelial neoplasia with 5-aminolevulinic acid photodynamic therapy.
- A Case Report of Successful Electroconvulsive Therapy for Severe Delirium in a Patient with Bipolar Disorder
- Catheter-related deep vein thrombosis complicated by iatrogenic pulmonary embolism after thrombectomy leading to hemodialysis failure and successful rescue by automated peritoneal dialysis : A case report
- A highly successful case report: a patient with intestinal hepatoid adenocarcinoma and liver metastases achieves excellent efficacy following immune-targeted therapy
- Successful Medical Management of Obstructive Mechanical Mitral Valve Thrombosis Using Low-Dose, Ultraslow Infusion Thrombolytic Therapy: A Case Report.
BibTeX
@article{marchionni2026decompensated,
title = {{Decompensated heart failure after one year of successful therapy with mavacamten: a case report.}},
author = {Giulia Marchionni and Lucrezia Netti and Silvia Stavagna and Cristina Chimenti},
journal = {European heart journal. Case reports},
year = {2026},
month = oct,
doi = {10.1093/ehjcr/ytag741},
url = {https://europepmc.org/article/MED/42953764},
note = {CC BY},
}
RIS
TY - JOUR
TI - Decompensated heart failure after one year of successful therapy with mavacamten: a case report.
AU - Giulia Marchionni
AU - Lucrezia Netti
AU - Silvia Stavagna
AU - Cristina Chimenti
PY - 2026
DA - 2026/10/07
JO - European heart journal. Case reports
DO - 10.1093/ehjcr/ytag741
UR - https://europepmc.org/article/MED/42953764
AB - Cardiac myosin inhibition is the first disease-specific therapeutic strategy for obstructive hypertrophic cardiomyopathy. Mavacamten, the first-in-class agent, has demonstrated an excellent safety profile and sustained efficacy in both clinical trials and real-world practice. However, its safe use requires careful monitoring and thorough patient education regarding potential drug-drug interactions. We report a case of acute heart failure occurring after long-term clinical stability on mavacamten following concomitant fluconazole administration. It is reasonable to assume that the pharmacokinetic interaction resulted in excessive mavacamten exposure, leading to transient systolic dysfunction, severe functional mitral regurgitation, and adverse left ventricular remodelling. This case report highlights the consequences of pharmacological interactions between mavacamten and a strong CYP2C19 inhibitor. Drug-drug interaction should always be considered and systematically excluded in a patient presenting with unexplained heart failure and left ventricular remodelling during mavacamten therapy.
SN - 2514-2119
ER -